Billing Code 4410-09-M

DEPARTMENT OF JUSTICE

DRUG ENFORCEMENT ADMINISTRATION

IMPORTER OF CONTROLLED SUBSTANCES

NOTICE OF APPLICATION

FISHER CLINICAL SERVICES, INC.

Pursuant to Title 21 Code of Federal Regulations

1301.34 (a), this is notice that on August 20, 2012, Fisher

Clinical Services, Inc., 7554 Schantz Road, Allentown,

Pennsylvania 18106, made application to the Drug

Enforcement Administration (DEA) for registration as an

importer of Tapentadol (9780), a basic class of controlled

substance listed in schedule II.

The company plans to import the listed controlled substance to conduct clinical trials.

Any bulk manufacturer who is presently, or is applying to be, registered with DEA to manufacture such basic class of controlled substance listed in schedule II, which falls under the authority of section 1002(a)(2)(B) of the Act (21 USC § 952(a)(2)(B)) may, in the circumstances set forth in 21 USC § 958(i), file comments or objections to the issuance of the proposed registration and may, at the

same time, file a written request for a hearing on such application pursuant to 21 CFR § 1301.43 and in such form as prescribed by 21 CFR § 1316.47.

Any such written comments or objections should be addressed, in quintuplicate, to the Drug Enforcement Administration, Office of Diversion Control, Federal Register Representative (ODL), 8701 Morrissette Drive, Springfield, Virginia 22152; and must be filed no later than [INSERT DATE 30 DAYS FROM DATE OF PUBLICATION].

This procedure is to be conducted simultaneously with, and independent of, the procedures described in 21 CFR § 1301.34(b), (c), (d), (e), and (f). As noted in a previous notice published in the Federal Register on September 23, 1975, 40 FR 43745-46, all applicants for registration to import a basic class of any controlled substances in schedules I or II are, and will continue to be, required to demonstrate to the Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration,

that the requirements for such registration pursuant to 21 USC § 958(a); 21 USC § 823(a); and 21 CFR § 1301.34(b), (c), (d), (e), and (f) are satisfied.

Joseph T. Rannazzisi
Deputy Assistant Administrator
Office of Diversion Control
Drug Enforcement Administration

DATED: November 1, 2012

[FR Doc. 2012-27437 Filed 11/08/2012 at 8:45 am; Publication Date: 11/09/2012]